Innate Pharma Ownership 2024 | Who Owns Innate Pharma Now?
Institutional Ownership
0.00%
Institutional Holders
2.00
Innate Pharma Institutional Shareholders
Institutional Shareholders by % of Total Shares
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| OPTIVER HOLDING B.V. | 0.11% | 0.00% | 87,352 | 16,788 | 23.79% | 169,463 | Jun 30, 2024 |
| EXCHANGE TRADED CONCEPTS, LLC | 0.11% | 0.00% | 86,237 | -26,833 | -23.73% | 167,300 | Jun 30, 2024 |
| MORGAN STANLEY | 0.05% | - | 43,524 | -600 | -1.36% | 84,437 | Jun 30, 2024 |
| BARCLAYS PLC | 0.00% | - | 412 | - | - | 1,000 | Jun 30, 2024 |
| UBS GROUP AG | 0.00% | - | 297 | 87 | 41.43% | 576 | Jun 30, 2024 |
| RHUMBLINE ADVISERS | 0.00% | - | 205 | - | - | 397 | Jun 30, 2024 |
| STEWARD PARTNERS INVESTMENT ADVISORY, LLC | 0.00% | - | 200 | - | - | 388 | Jun 30, 2024 |
| MILLENNIUM MANAGEMENT LLC | - | - | - | -10,579 | -100.00% | - | Jun 30, 2024 |
Innate Pharma's largest institutional shareholder is OPTIVER HOLDING B.V., holding 0.11% of the company's total share outstanding, currently valued at $169.46K. The top 10 institutional shareholders own together 0.27% of the company.
Institutional Shareholders by % of Total Assets
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| EXCHANGE TRADED CONCEPTS, LLC | 0.11% | 0.00% | 86,237 | -26,833 | -23.73% | 167,300 | Jun 30, 2024 |
| OPTIVER HOLDING B.V. | 0.11% | 0.00% | 87,352 | 16,788 | 23.79% | 169,463 | Jun 30, 2024 |
| MORGAN STANLEY | 0.05% | - | 43,524 | -600 | -1.36% | 84,437 | Jun 30, 2024 |
| STEWARD PARTNERS INVESTMENT ADVISORY, LLC | 0.00% | - | 200 | - | - | 388 | Jun 30, 2024 |
| RHUMBLINE ADVISERS | 0.00% | - | 205 | - | - | 397 | Jun 30, 2024 |
| BARCLAYS PLC | 0.00% | - | 412 | - | - | 1,000 | Jun 30, 2024 |
| UBS GROUP AG | 0.00% | - | 297 | 87 | 41.43% | 576 | Jun 30, 2024 |
| MILLENNIUM MANAGEMENT LLC | - | - | - | -10,579 | -100.00% | - | Jun 30, 2024 |
The largest Innate Pharma shareholder by % of total assets is EXCHANGE TRADED CONCEPTS, LLC. The company owns 86.24K shares of Innate Pharma (IPHA), representing 0.00% of its total assets.
Institutional Buyers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| OPTIVER HOLDING B.V. | 0.11% | 0.00% | 87,352 | 16,788 | 23.79% | 169,463 | Jun 30, 2024 |
| UBS GROUP AG | 0.00% | - | 297 | 87 | 41.43% | 576 | Jun 30, 2024 |
| BARCLAYS PLC | 0.00% | - | 412 | - | - | 1,000 | Jun 30, 2024 |
| RHUMBLINE ADVISERS | 0.00% | - | 205 | - | - | 397 | Jun 30, 2024 |
| STEWARD PARTNERS INVESTMENT ADVISORY, LLC | 0.00% | - | 200 | - | - | 388 | Jun 30, 2024 |
| MORGAN STANLEY | 0.05% | - | 43,524 | -600 | -1.36% | 84,437 | Jun 30, 2024 |
| MILLENNIUM MANAGEMENT LLC | - | - | - | -10,579 | -100.00% | - | Jun 30, 2024 |
| EXCHANGE TRADED CONCEPTS, LLC | 0.11% | 0.00% | 86,237 | -26,833 | -23.73% | 167,300 | Jun 30, 2024 |
As of Jun 30 2024, Innate Pharma's largest institutional buyer is OPTIVER HOLDING B.V.. The company purchased 16.79K stocks of IPHA, valued at $169.46K.
Institutional Sellers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| EXCHANGE TRADED CONCEPTS, LLC | 0.11% | 0.00% | 86,237 | -26,833 | -23.73% | 167,300 | Jun 30, 2024 |
| MILLENNIUM MANAGEMENT LLC | - | - | - | -10,579 | -100.00% | - | Jun 30, 2024 |
| MORGAN STANLEY | 0.05% | - | 43,524 | -600 | -1.36% | 84,437 | Jun 30, 2024 |
| STEWARD PARTNERS INVESTMENT ADVISORY, LLC | 0.00% | - | 200 | - | - | 388 | Jun 30, 2024 |
| RHUMBLINE ADVISERS | 0.00% | - | 205 | - | - | 397 | Jun 30, 2024 |
| BARCLAYS PLC | 0.00% | - | 412 | - | - | 1,000 | Jun 30, 2024 |
| UBS GROUP AG | 0.00% | - | 297 | 87 | 41.43% | 576 | Jun 30, 2024 |
| OPTIVER HOLDING B.V. | 0.11% | 0.00% | 87,352 | 16,788 | 23.79% | 169,463 | Jun 30, 2024 |
As of Jun 30 2024, Innate Pharma's biggest institutional seller is EXCHANGE TRADED CONCEPTS, LLC. The company sold -26.83K shares of IPHA, valued at $167.30K.
Institutional New positions
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|
Institutional Sold Out
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| MILLENNIUM MANAGEMENT LLC | - | - | - | -10,579 | -100.00% | - | Jun 30, 2024 |
Innate Pharma's largest sold out institutional shareholder by shares sold is MILLENNIUM MANAGEMENT LLC, sold -10.58K shares, valued at -, as of undefined.
Innate Pharma Mutual Fund Holders
| Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
|---|---|---|---|---|---|
| ALPS ETF Trust | 0.01% | 79,097 | - | - | Feb 29, 2024 |
| ETF Series Solutions | 0.00% | 55,168 | 8,842 | 19.09% | Feb 29, 2024 |
| TRUST FOR PROFESSIONAL MANAGERS | 0.00% | 22,465 | 14,838 | 194.55% | Feb 29, 2024 |
| iSHARES TRUST | 0.00% | 486,495 | - | - | Mar 31, 2024 |
Innate Pharma's largest mutual fund holder by % of total assets is "ALPS ETF Trust", owning 79.10K shares, compromising 0.01% of its total assets.
Innate Pharma Institutional Ownership Trends
Institutional Holdings Trend
| Date | Holdings | Change % |
|---|---|---|
| 30 Jun, 24 | 2 | -77.78% |
| 31 Mar, 24 | 9 | 12.50% |
| 31 Dec, 23 | 8 | - |
| 30 Sep, 23 | 8 | -11.11% |
| 30 Jun, 23 | 9 | 12.50% |
| 31 Mar, 23 | 8 | -20.00% |
| 31 Dec, 22 | 10 | 11.11% |
| 30 Sep, 22 | 9 | -25.00% |
| 30 Jun, 22 | 12 | - |
| 31 Mar, 22 | 12 | -20.00% |
| 31 Dec, 21 | 15 | -16.67% |
| 30 Sep, 21 | 18 | 260.00% |
| 30 Jun, 21 | 5 | -28.57% |
| 31 Mar, 21 | 7 | 75.00% |
| 31 Dec, 20 | 4 | -33.33% |
| 30 Sep, 20 | 6 | -14.29% |
| 30 Jun, 20 | 7 | -30.00% |
| 31 Mar, 20 | 10 | -16.67% |
| 31 Dec, 19 | 12 | - |
As of 30 Jun 24, 2 institutions are holding Innate Pharma's shares, representing a decrease of -77.78% compared to the previous quarter.
Shares Outstanding Trend
| Date | Shares Outstanding | Change % |
|---|---|---|
| 30 Jun, 24 | 405 | -99.84% |
| 31 Mar, 24 | 253,918 | 96.97% |
| 31 Dec, 23 | 128,912 | -59.51% |
| 30 Sep, 23 | 318,407 | 35.34% |
| 30 Jun, 23 | 235,270 | -40.73% |
| 31 Mar, 23 | 396,953 | -0.70% |
| 31 Dec, 22 | 399,757 | -57.66% |
| 30 Sep, 22 | 944,107 | -1.07% |
| 30 Jun, 22 | 954,312 | 0.22% |
| 31 Mar, 22 | 952,242 | -31.50% |
| 31 Dec, 21 | 1,390,120 | 47.40% |
| 30 Sep, 21 | 943,114 | 953.29% |
| 30 Jun, 21 | 89,540 | -49.13% |
| 31 Mar, 21 | 176,028 | -87.39% |
| 31 Dec, 20 | 1,395,579 | -17.12% |
| 30 Sep, 20 | 1,683,925 | -41.36% |
| 30 Jun, 20 | 2,871,409 | -60.88% |
| 31 Mar, 20 | 7,340,005 | -4.86% |
| 31 Dec, 19 | 7,714,580 | - |
Innate Pharma (IPHA) has 405.00 shares outstanding as of 30 Jun 24, down -99.84% compared to the previous quarter.
Institutional Ownership Trend
| Date | Ownership % | Change % |
|---|---|---|
| 30 Jun, 24 | 0.00% | 0.51% |
| 31 Mar, 24 | 0.32% | 1240.88% |
| 31 Dec, 23 | 0.16% | 102.15% |
| 30 Sep, 23 | 0.40% | 460.53% |
| 30 Jun, 23 | 0.29% | 137.18% |
| 31 Mar, 23 | 0.46% | 185.96% |
| 31 Dec, 22 | 0.50% | 35.00% |
| 30 Sep, 22 | 1.19% | 83.31% |
| 30 Jun, 22 | 1.20% | 83.52% |
| 31 Mar, 22 | 1.20% | 39.20% |
| 31 Dec, 21 | 1.75% | 124.31% |
| 30 Sep, 21 | 1.19% | 9217.28% |
| 30 Jun, 21 | 0.11% | 228.12% |
| 31 Mar, 21 | 0.22% | 7.13% |
| 31 Dec, 20 | 1.77% | 38.81% |
| 30 Sep, 20 | 2.13% | 16.11% |
| 30 Jun, 20 | 3.64% | 3.02% |
| 31 Mar, 20 | 10.97% | 8.25% |
| 31 Dec, 19 | 11.53% | - |
As of 30 Jun 24, Innate Pharma is held by 0.00% institutional shareholders, representing a 0.51% growth compared to 31 Mar 24.
Institutional Increased Positions Trend
| Date | Increased Positions | Change % |
|---|---|---|
| 30 Jun, 24 | - | -100.00% |
| 31 Mar, 24 | 4 | 100.00% |
| 31 Dec, 23 | 2 | 100.00% |
| 30 Sep, 23 | 1 | -66.67% |
| 30 Jun, 23 | 3 | 50.00% |
| 31 Mar, 23 | 2 | -60.00% |
| 31 Dec, 22 | 5 | 25.00% |
| 30 Sep, 22 | 4 | -33.33% |
| 30 Jun, 22 | 6 | 20.00% |
| 31 Mar, 22 | 5 | -44.44% |
| 31 Dec, 21 | 9 | -40.00% |
| 30 Sep, 21 | 15 | - |
| 30 Jun, 21 | - | -100.00% |
| 31 Mar, 21 | 5 | 400.00% |
| 31 Dec, 20 | 1 | - |
| 30 Sep, 20 | 1 | -50.00% |
| 30 Jun, 20 | 2 | -50.00% |
| 31 Mar, 20 | 4 | -66.67% |
| 31 Dec, 19 | 12 | - |
- institutional shareholders have increased their position in IPHA stock as of 30 Jun 24 compared to 4 in the previous quarter (a -100.00% decrease).
Institutional Reduced Positions Trend
| Date | Reduced Positions | Change % |
|---|---|---|
| 30 Jun, 24 | - | -100.00% |
| 31 Mar, 24 | 2 | -33.33% |
| 31 Dec, 23 | 3 | - |
| 30 Sep, 23 | 3 | -25.00% |
| 30 Jun, 23 | 4 | 33.33% |
| 31 Mar, 23 | 3 | -25.00% |
| 31 Dec, 22 | 4 | - |
| 30 Sep, 22 | 4 | - |
| 30 Jun, 22 | 4 | -20.00% |
| 31 Mar, 22 | 5 | - |
| 31 Dec, 21 | 5 | 66.67% |
| 30 Sep, 21 | 3 | -25.00% |
| 30 Jun, 21 | 4 | 100.00% |
| 31 Mar, 21 | 2 | - |
| 31 Dec, 20 | 2 | - |
| 30 Sep, 20 | 2 | - |
| 30 Jun, 20 | - | -100.00% |
| 31 Mar, 20 | 5 | - |
| 31 Dec, 19 | - | - |
- institutional shareholders have reduced their position in IPHA stock as of 30 Jun 24 compared to 2 in the previous quarter (a -100.00% decrease).
All Institutional Ownership Trend Data
| Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| 30 Jun, 24 | 2 | -77.78% | 405 | -99.84% | 0.00% | 0.51% | - | -100.00% | - | -100.00% |
| 31 Mar, 24 | 9 | 12.50% | 253,918 | 96.97% | 0.32% | 1240.88% | 4 | 100.00% | 2 | -33.33% |
| 31 Dec, 23 | 8 | - | 128,912 | -59.51% | 0.16% | 102.15% | 2 | 100.00% | 3 | - |
| 30 Sep, 23 | 8 | -11.11% | 318,407 | 35.34% | 0.40% | 460.53% | 1 | -66.67% | 3 | -25.00% |
| 30 Jun, 23 | 9 | 12.50% | 235,270 | -40.73% | 0.29% | 137.18% | 3 | 50.00% | 4 | 33.33% |
| 31 Mar, 23 | 8 | -20.00% | 396,953 | -0.70% | 0.46% | 185.96% | 2 | -60.00% | 3 | -25.00% |
| 31 Dec, 22 | 10 | 11.11% | 399,757 | -57.66% | 0.50% | 35.00% | 5 | 25.00% | 4 | - |
| 30 Sep, 22 | 9 | -25.00% | 944,107 | -1.07% | 1.19% | 83.31% | 4 | -33.33% | 4 | - |
| 30 Jun, 22 | 12 | - | 954,312 | 0.22% | 1.20% | 83.52% | 6 | 20.00% | 4 | -20.00% |
| 31 Mar, 22 | 12 | -20.00% | 952,242 | -31.50% | 1.20% | 39.20% | 5 | -44.44% | 5 | - |
| 31 Dec, 21 | 15 | -16.67% | 1,390,120 | 47.40% | 1.75% | 124.31% | 9 | -40.00% | 5 | 66.67% |
| 30 Sep, 21 | 18 | 260.00% | 943,114 | 953.29% | 1.19% | 9217.28% | 15 | - | 3 | -25.00% |
| 30 Jun, 21 | 5 | -28.57% | 89,540 | -49.13% | 0.11% | 228.12% | - | -100.00% | 4 | 100.00% |
| 31 Mar, 21 | 7 | 75.00% | 176,028 | -87.39% | 0.22% | 7.13% | 5 | 400.00% | 2 | - |
| 31 Dec, 20 | 4 | -33.33% | 1,395,579 | -17.12% | 1.77% | 38.81% | 1 | - | 2 | - |
| 30 Sep, 20 | 6 | -14.29% | 1,683,925 | -41.36% | 2.13% | 16.11% | 1 | -50.00% | 2 | - |
| 30 Jun, 20 | 7 | -30.00% | 2,871,409 | -60.88% | 3.64% | 3.02% | 2 | -50.00% | - | -100.00% |
| 31 Mar, 20 | 10 | -16.67% | 7,340,005 | -4.86% | 10.97% | 8.25% | 4 | -66.67% | 5 | - |
| 31 Dec, 19 | 12 | - | 7,714,580 | - | 11.53% | - | 12 | - | - | - |
Innate Pharma Peer Ownership
| Ticker | Company |
|---|---|
| CYT | Cyteir Therapeutics, Inc. |
| DYAI | Dyadic International, Inc. |
| IPSC | Century Therapeutics, Inc. |
| INBX | Inhibrx, Inc. |
| CSBR | Champions Oncology, Inc. |
| HCWB | HCW Biologics Inc. |
| MNOV | MediciNova, Inc. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| MOLN | Molecular Partners AG |
| ADXN | Addex Therapeutics Ltd |
| PRDS | Pardes Biosciences, Inc. |
| STTK | Shattuck Labs, Inc. |
| ELYM | Eliem Therapeutics, Inc. |
IPHA Ownership FAQ
Who Owns Innate Pharma?
Innate Pharma is owned by institutional shareholders (0.00%), insiders (0.00%), and public (100.00%). The largest institutional shareholder of Innate Pharma is OPTIVER HOLDING B.V. (0.11% of total shares) and the top mutual fund owner is ALPS ETF Trust (0.01% of total shares).
Who are the major institutional shareholders of Innate Pharma?
Innate Pharma's major institutional shareholders are OPTIVER HOLDING B.V., EXCHANGE TRADED CONCEPTS, LLC, MORGAN STANLEY, BARCLAYS PLC, and UBS GROUP AG. The top five shareholders own together 0.27% of the company's share outstanding.
How many Innate Pharma shareholders are there?
As of Jun 2024, there are 2 institutional shareholders of Innate Pharma.
What percentage of Innate Pharma is owned by OPTIVER HOLDING B.V?
OPTIVER HOLDING B.V owns 87.35K shares of Innate Pharma, representing 0.11% of the company's total shares outstanding, valued at $169.46K (as of Jun 2024).
What percentage of Innate Pharma is owned by EXCHANGE TRADED CONCEPTS, LLC?
As of Jun 2024, EXCHANGE TRADED CONCEPTS, LLC holds 86.24K shares of Innate Pharma (IPHA), compromising 0.11% of the company, valued at $167.3K.
What percentage of Innate Pharma is owned by MORGAN STANLEY?
MORGAN STANLEY is the third largest holder of Innate Pharma. The company owns 43.52K of the company's shares outstanding (worth $84.44K).